返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® EP's Project "Cardiac Telemedicine System Based on Smart Device and Cloud" Wins 2016 Shanghai Internet of Things Innovative Product Award

[2017-06-07] 

Shanghai, China – On May 17, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") was granted the 2016 Shanghai Internet of Things Innovative Product Award for its project "Cardiac Telemedicine System Based on Smart Device and Cloud." The project connects hospitals, patients, and physicians by ECG Internet of Things to share data and information regarding ECG collecting, disease diagnosis, professional guiding and post-operation follow-up, to enhance the efficiency of the use of medical resources.
 
Shanghai Internet of Things Industry Association aims to promote the development of Internet of Things. Under the direction of Shanghai Municipal Commission of Economy and Information Technology, the association selects "Internet of Things Model Project" in Shanghai every year since 2013. In 2016, a total of 32 enterprises shared four categories of awards including Shanghai Internet of Things Model Project Award, Shanghai Internet of Things Innovation Award, Shanghai Internet of Things Key Product Award, and Shanghai Internet of Things Innovative Product Award. Xinhua Fu, Deputy Director of Shanghai Municipal Commission of Economy and Information Technology, noted that Internet of Things is a strategic area Shanghai should seize to maintain its leading position in science and technology innovation. From the end of 2009, Shanghai has been planning to promote the development of the Internet of Things industry. Up to date, there are more than 700 Internet of Things enterprises in Shanghai, and the market value of its Internet of Things industry has reached 100 billion yuan with a growth rate of 30% annually.
 
MicroPort® EP's project "Cardiac Telemedicine System Based on Smart Device and Cloud" is the only one related to medical application among the eight projects that obtained Shanghai Internet of Things Innovative Product Award. The project is based on a mobile medical device of MicroPort® EP - ECG Patch. Firstly, the patch is put on the patient's chest to collect ECG, and then the data will be transmitted to a big data platform where it will be automatically analyzed and classified to provide reference for the doctors. If anything wrong is found, the device will recommend doctors according to the type of disease diagnosed and the doctor can use a special App to get connected with the patient and guide him/her to seek medical advice. Once the patient receives operation, the device can record follow-up data accordingly by collecting the patient's ECG regularly. The App also makes follow-up easier as it can directly show the electrocardiography or the electrocardiographic report once receiving the patient's ECG data.
 
Dr. Yiyong Sun, President of MicroPort® EP, said: "The award of the project ‘Cardiac Telemedicine System Based on Smart Device and Cloud' shows that smaller, wireless and smarter electrophysiological medical hardware has a promising future in the era of mobile internet. In the future, MicroPort® EP will further leverage the strength of MicroPort® to combine the professional medical service with modern IT technology including the Internet, the Internet of Things, big data analysis to develop more innovations of healthcare Internet of Things to benefit more patients and doctors."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosts 2017 Coronary Product Distributor Conference
[Next]:First Patient Enrolled for Firehawk® Malaysian TARGET MR Clinical Trial